Acrivon Therapeutics
PublicAcrivon Therapeutics is now publicly traded
The data on this page reflects Acrivon Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Nov 14, 2022
Last Round
PIPE
Apr 9, 2024
Total Funding Raised
$344.9M
Company Overview
Acrivon Therapeutics (NAS: ACRV) is a biopharmaceutical company focused on developing targeted oncology therapies matched to patients based on a proteomics-based responder identification platform.
Sector
Healthcare
AI Layer
Application
Keywords
Acrivon Therapeutics Comparables
Compare Acrivon Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| FoRx Therapeutics | 67% | |
| Sentinel Oncology | 56% | |
| Arum Therapeutics | 54% |
Acrivon Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| PIPE | Apr 9, 2024 | ||||
| IPO | Nov 14, 2022 | ||||
| Series B | Nov 11, 2021 | ||||
| Series A | Feb 1, 2021 |
Acrivon Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| Chione Ltd | Series A, Series B |
| RA Capital Advisors | Series B |
| RA Capital Management | PIPE, Series B |
| Perceptive Advisors | PIPE, Series B |
| OrbiMed | Series B |
| Paradigm BioCapital | PIPE |
Acrivon Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access